Press release
11.10.2021 To the attention of interested persons EMA receives application for marketing authorisation for Ronapreve (casirivimab / imdevimab) for treatment […]
11.10.2021 To the attention of interested persons EMA receives application for marketing authorisation for Ronapreve (casirivimab / imdevimab) for treatment […]
07.10.2021 To the attention of interested persons Additional manufacturing site for COVID-19 Vaccine Janssen download document …
04.10.2021 To the attention of interested persons Comirnaty and Spikevax: EMA recommendations on extra doses and boosters download document …
04.10.2021 To the attention of interested persons EMA receives application for marketing authorisation for Regkirona (regdanvimab) for treating patients with […]
01.10.2021 To the attention of interested persons Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 27-30 September 2021 download […]
01.10.2021 To the attention of interested persons EMA starts review of meningioma risk with nomegestrol- and chlormadinone-containing medicines download document […]
27.09.2021 To the attention of interested persons EMA evaluating data on booster dose of COVID-19 vaccine Spikevax download document …
09.09.2021 To the attention of interested persons Increase in manufacturing capacity for COVID-19 vaccine from BioNTech/Pfizer download document …
06.09.2021 To the attention of interested persons EMA evaluating data on booster dose of COVID-19 vaccine Comirnaty. download document …
03.09.2021 To the attention of interested persons Shortage of RoActemra (tocilizumab) download document …